Brief: Tempest To Report Early Results From Global Randomized Phase 1B/2 Combination Study Of Tpst-1120 In First-Line Hepatocellular Carcinoma
27/04/2023 22:44
April 27 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST TO REPORT EARLY RESULTS FROM GLOBAL RANDOMIZED
PHASE
1B/2 COMBINATION STUDY OF TPST-1120 IN FIRST-LINE HEPATOCELLULAR
CARCINOMA
Source text for Eikon: ID:nGNX6hXCwm
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T